Volume 8, Issue 1 (3-2020)                   Jorjani Biomed J 2020, 8(1): 34-40 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Golsha R, Gorgitabar N, Khodabakhshi B, Abbasi A, Kalani H. Mucormycosis prevalence in diabetic individuals in the northeast of Iran: a 10-year retrospective study. Jorjani Biomed J. 2020; 8 (1) :34-40
URL: http://goums.ac.ir/jorjanijournal/article-1-716-en.html
1- Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2- Clinical Research Development Center, Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran , hamed.kalani@yahoo.com
Abstract:   (346 Views)
Background and objective: Currently, due to an increase in the number of individuals with immune deficiency, long-term chemotherapy, and underlying diseases, an appropriate situation has been provided for the development of opportunistic infections, including fungal infections. This study was conducted with the aim of evaluating clinical symptoms, laboratory findings, and the treatment outcome of mucormycosis in diabetic individuals.
Methods: In this cross-sectional retrospective study, all recorded cases of mucormycosis in the health centers of Gorgan city, northeast of Iran, in diabetic individuals were extracted during 15 years from 2002 to 2016. All information was extracted from patient-related records and then was analyzed. In the period from 2002 to 2016, 12 diabetic individuals with mucormycosis were referred to health centers.
Results: There were statistically significant differences in the categories of sex, residence, education, taking drug, addiction, diabetes status, methods of diagnosis, involved area with mucormycosis, treatment type of mucormycosis, and treatment outcome of mucormycosis. Furthermore, no statistically significant difference was observed in the categories of age, underlying diseases (other than diabetes), hospitalization, and diagnostic time.
Conclusion: Due to the rareness or lack of an appropriate diagnostic method, and in addition, due to lack of an appropriate treatment, attention should be paid to invasive mucormycosis in individuals with immunodeficiency.
Keywords: diabetes [MeSH], gorgan , Iran [MeSH], mucormycosis [MeSH],
Full-Text [PDF 206 kb]   (111 Downloads) |   |   Full-Text (HTML)  (43 Views)  
Type of Article: Original article | Subject: Health
Received: 2020/01/30 | Revised: 2020/02/11 | Accepted: 2020/02/29

1. Lanternier F, Cypowyj S, Picard C, Bustamante J, Lortholary O, Casanova JL et al. Primary immunodeficiencies underlying fungal infections. Curr opini pediatr. 2013;25(6):736-47. [DOI: 10.1097/MOP.0000000000000031] [DOI:10.1097/MOP.0000000000000031]
2. Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am. 2000;33(2):349-65. [DOI: 10.1016/s0030-6665(00)80010-9] [DOI:10.1016/S0030-6665(00)80010-9]
3. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr opini infect dis. 2004;17(6):517-25. [DOI: 10.1097/00001432-200412000-00003] [DOI:10.1097/00001432-200412000-00003]
4. Ruoppi P, Dietz A, Nikanne E, Seppa J, Markkanen H, Nuutinen J. Paranasal sinus mucormycosis: a report of two cases. Acta Otolaryngol. 2001;121(8):948-52. [DOI:10.1080/000164801317166844]
5. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012;54 Suppl 1(Suppl 1):S16-S22. [DOI: 10.1093/cid/cir865] [DOI:10.1093/cid/cir865]
6. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in Solid Organ Transplant Recipients in a Tertiary Transplant Center and Review of the Literature. Am J Transplant. 2006;6(10):2365-74. [DOI: 10.1111/j.1600-6143.2006.01496.x] [DOI:10.1111/j.1600-6143.2006.01496.x]
7. Dave SP, Vivero RJ, Roy S. Facial cutaneous mucormycosis in a full-term infant. Arch Otolaryngol Head Neck Surg. 2008;134(2):206-9. [DOI: 10.1001/archoto.2007.48] [DOI:10.1001/archoto.2007.48]
8. Al-Obaidi M, Younes P, Ostrosky-Zeichner 138 L. Post-exposure prophylaxis with isavuconazole after occupational exposure to Rhizopus. Oxford medical case reports. 2018;2018(10):omy062. [DOI: 10.1093/omcr/omy062] [DOI:10.1093/omcr/omy062]
9. Turunc T, Demiroglu YZ, Aliskan H, Colakoglu S, Arslan H. Eleven cases of mucormycosis with atypical clinical manifestations in diabetic patients. Diabetes Res Clin Pract. 2008;82(2):203-8. [DOI: 10.1016/j.diabres.2008.07.011] [DOI:10.1016/j.diabres.2008.07.011]
10. You WP, Henneberg M. Type 1 diabetes prevalence increasing globally and regionally: the role of natural selection and life expectancy at birth. BMJ open diab res ca. 2016;4(1):e000161. [DOI: 10.1136/bmjdrc-2015-000161] [DOI:10.1136/bmjdrc-2015-000161]
11. Ilyas R, Wallis R, Soilleux EJ, Townsend P, Zehnder D, Tan BK et al. High glucose disrupts oligosaccharide recognition function via competitive inhibition: a potential mechanism for immune dysregulation in diabetes mellitus. Immunobiology. 2011;216(1-2):126-31. [DOI: 0.1016/j.imbio.2010.06.002] [DOI:10.1016/j.imbio.2010.06.002]
12. Ata A, Lee J, Bestle SL, Desemone J, Stain SC. Postoperative hyperglycemia and surgical site infection in general surgery patients. Arch Surg. 2010;145(9):858-64. [DOI: 10.1001/archsurg.2010.179] [DOI:10.1001/archsurg.2010.179]
13. de Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis. 2002;2:1. [DOI: 10.1186/1471-2334-2-1] [DOI:10.1186/1471-2334-2-1]
14. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin microbiol rev. 2000;13(2):236-301. [DOI: 10.1128/cmr.13.2.236-301.2000] [DOI:10.1128/CMR.13.2.236-301.2000]
15. Kolekar JS. Rhinocerebral mucormycosis: a 159 retrospective study. Indian j otolaryngol. 2015;67(1):93-6. [DOI:10.1007/s12070-014-0804-5]
16. Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis. 2012; 54 Suppl 1:S35-43. [DOI: 10.1093/cid/cir880] [DOI:10.1093/cid/cir880]
17. Afroze SN, Korlepara R, Rao GV, Madala J. Mucormycosis in a Diabetic Patient: A Case Report with an Insight into Its Pathophysiology. Contemp clin dent. 2017;8(4):662-6. [DOI: 10.4103/ccd.ccd_558_17] [DOI:10.4103/ccd.ccd_558_17]
18. Gutiérrez-Delgado EM, Treviño-González JL, Montemayor-Alatorre A, Ceceñas-Falcón LA, Ruiz-Holguín E, Andrade-Vázquez CJ et al. Chronic rhino-orbito-cerebral mucormycosis: A case report and review of the literature. Ann surg. 2016;6:87-91. [DOI: 10.1016/j.amsu.2016.02.003] [DOI:10.1016/j.amsu.2016.02.003]
19. Mohammadi R, Meidani M, Mostafavizadeh K, Iraj B, Hamedani P, Sayedain SM et al. Case series of rhinocerebral mucormycosis occurring in diabetic patients. Caspian journal of internal medicine. 2015;6(4):243-6.
20. Iqbal N, Irfan M, Jabeen K, Kazmi MM, Tariq MU. Chronic pulmonary mucormycosis: an emerging fungal infection in diabetes mellitus. J thorac dis. 2017;9(2):E121- e5. [DOI: 10.21037/jtd.2017.02.31] [DOI:10.21037/jtd.2017.02.31]
21. Parham M, Abbasi M, Alipour Nodoushan K, Noorozi M, Mehran N. A Case Report of Rare Tracheal Mucormycosis in a Diabetic Patient. Qom Univ Med Sci J. 2009;3(3):57-60.
22. Kashkouli MB, Abdolalizadeh P, Oghazian M, Hadi Y, Karimi N, Ghazizadeh M. Outcomes and factors affecting them in patients with rhino-orbito-cerebral mucormycosis. Br j ophthalmol. 2018. [DOI: 10.1136/bjophthalmol-2018-312688] [DOI:10.1136/bjophthalmol-2018-312688]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2020 All Rights Reserved | Jorjani Biomedicine Journal

Designed & Developed by : Yektaweb